

Hsil Limited January 24, 2022

Update on slump sale of HSIL's BPD Undertaking to Brilloca Ltd.

The company has intimated the stock exchanges on Jan 15, 2022 regarding transfer of its business of manufacturing, on contract basis, of sanitaryware, faucets and plastic pipes (PVC and CPVC) and fittings (BPD Undertaking) to Brilloca Limited (Brilloca), on a slump sale basis, for a lump sum consideration of Rs 630.00 crore. With the proposed transaction, the Building Products division's entire operating facilities of HSIL will be transferred to Brilloca Ltd leaving apart some land parcels on which Brilloca Ltd. will continue to pay lease rentals to HSIL Ltd. Going forward, HSIL will completely be a packaging company.

The entire consideration will be paid by Brilloca in Cash to HSIL Ltd and HSIL will be utilizing the funds to repay long term and working capital borrowings which pertain to BPD division. This is expected to result in deleveraging of balance sheet of HSIL Ltd to an extent and will reduce the related party transaction at the group level and will aid in the re-alignment of business segments in order to reap synergistic benefits at the respective entity level.

The agreement for slump sale is yet to be executed. The transaction is subject to the satisfactory completion of the condition's precedent by the parties (including receipt of approval of the shareholders, lenders, and other necessary approvals required for the slump sale) in accordance with the provisions of the business transfer agreement to be executed. The transaction is expected to be completed by March 31, 2022.

CARE has taken into account the said announcement by the company and will continue to closely monitor the progress of the said deal.

Detailed Rationale & Key Rating Drivers

The ratings assigned to the bank facilities of HSIL Limited (HSIL) continues to derive strength from its experienced promoters, its established track record of operations, its strong market position and established relations with its institutional clients in the container glass segment. The ratings also factor in the diversified presence in the packaging products segments and expansion done by the group in the security caps & closures to complement its container glass segment & its comfortable financial risk profile.

These rating strengths are, however, partially off-set by its moderate capital structure due to ongoing debt funded capital expenditure, susceptibility of HSIL's financial profile to raw material and fuel price fluctuation risk and foreign exchange fluctuation risk.

The previous press release is available on the following link: Click here

Analytical approach:

Standalone. The ratings however used to factor in the linkages with its group companies (SHIL & Brilloca rated CARE A+; Stable/A1+) owing to common management and strong business & operational linkages with them.

Note: Post this announcement, the approach for HSIL Ltd will be 'Standalone' going forward as the operational linkages will not be there as the BPD segment will not form part of HSIL.



Contact us

Media Contact

Name: Mradul Mishra Contact no.: +91-22-6754 3573 Email ID: mradul.mishra@careedge.in

Analyst Contact

Name: Ravleen Sethi Contact no.: +91-11-4533 3251 Email ID: ravleen.sethi@careedge.in

Relationship Contact

Name: Swati Agrawal Contact no.: +91-11-4533 3200 Email ID: swati.agrawal@careedge.in

About CARE Ratings Limited:

Established in 1993, CARE Ratings Ltd. is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India (SEBI), it has also been acknowledged as an External Credit Assessment Institution (ECAI) by the Reserve Bank of India (RBI). With an equitable position in the Indian capital market, CARE Ratings Limited provides a wide array of credit rating services that help corporates to raise capital and enable investors to make informed decisions backed by knowledge and assessment provided by the company.

With an established track record of rating companies over almost three decades, we follow a robust and transparent rating process that leverages our domain and analytical expertise backed by the methodologies congruent with the international best practices. CARE Ratings Limited has had a pivotal role to play in developing bank debt and capital market instruments including CPs, corporate bonds and debentures, and structured credit.

Disclaimer

The ratings issued by CARE Ratings Limited are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse or recall the concerned bank facilities or to buy, sell or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings Limited has based its ratings/outlooks based on information obtained from reliable and credible sources. CARE Ratings Limited does not, however, guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings Limited have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings Limited or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating /outlook assigned by CARE Ratings Limited is, inter-alia, based on the capital deployed by the partners/proprietor and the current financial strength of the firm. The rating/outlook may undergo a change in case of withdrawal of capital or the unsecured loans brought in by the partners/proprietor in addition to the financial performance and other relevant factors. CARE Ratings Limited is not responsible for any errors and states that it has no financial liability whatsoever to the users of CARE Ratings Limited's rating.

Our ratings do not factor in any rating related trigger clauses as per the terms of the facility/instrument, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and if triggered, the ratings may see volatility and sharp downgrades.

**For detailed Rationale Report and subscription information, please contact us at <u>www.careedge.in</u>